COVID-19 has changed many aspects of life and business and particularly the case in sleep medicine. With many sleep doctors providing virtual consultations to reduce risks, remote care for sleep disorders has become mainstream. At MEDICA 2021, from November 15 to 18 in Messe Düsseldorf, Somnics will present the newest developments of its iNAP Remote OSA Therapy Services.
The innovative functions include the iNAP Lab+ mobile app, sleep management platform on the cloud, and remote pressure adjustments by physicians demonstrate their long-term vision for creating the industry value chains for sleep disorders management.
Over recent years, Somnics, Inc. has successfully obtained regulatory approval in the U.S. and Europe for its signature product, the iNAP One Sleep Therapy System. With entry into the German market and the establishment of the U.S. subsidiary, Somnics Health, the company has accumulated extensive market experience and clinical feedback. This has helped its team enhance the iNAP user experience by centering on patients. For example, the new generation Oral Interface, I08
, improves the fitting and fixation by providing 80 size combinations according to the physician’s evaluation. The Omni9 Home Sleep Testing Device
helps track patients' sleep and biological data remotely, while the iNAP remote sleep management system
which meets the post-COVID-19 medical megatrend is also the highlight of Somnics’ achievements be presented at MEDICA 2021.
Somnics iNAP remote sleep management system is based on iNAP Lab+ APP
installed on the mobile phone and connected with the oximeter, health bracelet, and sleep ring or with Omni9 so that users can record and stay on top of the biological data during sleep for obstructive sleep apnea (OSA) therapy. Then, physicians can analyze and instruct from the cloud, adjust the negative pressure parameters remotely, and optimize OSA treatment effectiveness via the iNAP remote sleep management system.
Somnics’s iNAP Lab+ remote OSA therapy services include a well-developed diagnosis, treatment, and monitoring features. The service is scheduled for launch in the U.S. and Taiwan by the end of this year so that patients can enjoy better OSA negative pressure therapy. The company hopes to establish cooperative ties with international medical professionals to promote this forward-looking and convenient solution
at the major annual exhibition, MEDICA 2021 in Germany.
Exhibitor Data Sheet